-+ 0.00%
-+ 0.00%
-+ 0.00%

LifeSci Capital Initiates Coverage On Apnimed with Outperform Rating, Announces Price Target of $50

Benzinga·08/25/2026 15:18:38
Listen to the news
LifeSci Capital analyst Francois Brisebois initiates coverage on Apnimed (NASDAQ:APMD) with a Outperform rating and announces Price Target of $50.